6 Amendments of Seb DANCE related to 2017/2951(RSP)
Amendment 3 #
Recital B
B. whereas cost of a full vaccines package for one child, even at the lowest global prices, has increased by a factor of 68 from 2001 to 2014; whereas this price increase is unjustifiable and incompatible with the Sustainable Development Goal to ensure healthy lives and promote well- being at all ages;
Amendment 40 #
Paragraph 8
8. Recalls the importance of the Clinical Trials Regulation in stimulating and facilitating research into new vaccinations and ensuring transparency of results of clinical trials; calls on the Commission and the European Medicines Agency to implement the Clinical Trials Regulation without further delay; in particular through setting up the European Portal and Database (EUPD) whose implementation has seen significant delays of over two years;
Amendment 41 #
Paragraph 8 – subparagraph 1 (new)
Further calls upon all parties involved to ensure that the current process of relocating the EMA away from London does not cause any additional disruption or delays to the work of the Agency;
Amendment 58 #
Paragraph 12 a (new)
12 a. Emphasises the need for inclusive, factual and science-based information to citizens; calls on the Commission and Member States to facilitate dialogue with stakeholders from civil society, grass root movements, academia, media and national health authorities in order to combat unreliable, misleading and unscientific information on vaccination;
Amendment 64 #
Paragraph 13
13. Is concerned about the high prices of some life-saving vaccines and that this risks further exacerbating existing health inequalities in society; calls on the Commission and the Member States to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicines;
Amendment 73 #
Paragraph 15 a (new)
15 a. Deplores the persisting inequalities between women and men in participation in clinical trials, which may hinder medicinal research and the development of vaccines for diseases where a majority of patients are women; calls on the Commission and Member States to take measures to eliminate this discriminating gender gap;